Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02398240 · ClinicalTrials.gov registry record · Phase 2
Brentuximab for Newly Diagnosed Hodgkin Disease
A Phase 2 study of Hodgkin Lymphoma, sponsored by Mitchell Cairo.
- Completed
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
- 1
- Study location
NCT02398240: Completed Phase 2 study of Hodgkin Lymphoma, sponsored by Mitchell Cairo.
NCT02398240 is a Phase 2 study of Hodgkin Lymphoma that has completed, run by Mitchell Cairo. The registered enrollment target is 40 participants, below the 165-participant average among 71 other Hodgkin Lymphoma trials with a reported enrollment target (76% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02398240, a Phase 2 study of Hodgkin Lymphoma, has completed, sponsored by Mitchell Cairo.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
The addition of Brentuximab vedotin (Bv) to combination chemotherapy will be safe, well tolerated and effective in children, adolescents and young adults with all stages of newly diagnosed Hodgkin lymphoma (HL).
Primary Outcome
Adverse events will be monitored each cycle to determine if there are any events related possibly, probably or definitely related to study therapy
Conditions Studied
Interventions
- DRUG Doxorubicin
- DRUG Rituximab
- DRUG Vincristine
- DRUG Brentuximab Vedotin
Study Locations (1)
New York
- New York Medical College - Valhalla
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2015-05 |
| Est. Completion | 2022-12 |
| Phase | Phase 2 |
What the finished NCT02398240 record still lists
NCT02398240 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 165-participant average among 71 other Hodgkin Lymphoma trials with a reported enrollment target (76% lower).
The record links to 1 condition, with Hodgkin Lymphoma appearing as the primary indexed condition, and to 4 interventions - of which Doxorubicin is the first listed.
NCT02398240 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT02398240 about?
NCT02398240 is a clinical study titled "Brentuximab for Newly Diagnosed Hodgkin Disease". The addition of Brentuximab vedotin (Bv) to combination chemotherapy will be safe, well tolerated and effective in children, adolescents and young adults with all stages of newly diagnosed Hodgkin lymphoma (HL).
What is the current status of trial NCT02398240?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2015-05. Estimated completion is 2022-12.
What conditions does trial NCT02398240 study?
This clinical trial studies the following conditions: Hodgkin Lymphoma.
What interventions are being tested in trial NCT02398240?
The interventions under investigation include: Doxorubicin (DRUG), Rituximab (DRUG), Vincristine (DRUG), Brentuximab Vedotin (DRUG).
Who is sponsoring clinical trial NCT02398240?
This trial is sponsored by Mitchell Cairo, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02398240 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hodgkin Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02398240's enrollment target sits among peer trials
40 41st of 71 higher than 30 of 71 other Hodgkin Lymphoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hodgkin Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Chemoradiotherapy With Targeted Immunotherapy in Pediatric Lymphoma
RECRUITING · Phase 2
-
A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHL
RECRUITING · Phase 2
-
BrECADD Therapy in Stage 2 B-IV Hodgkin Lymphoma
RECRUITING · Phase 2
-
Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies
RECRUITING · Phase 2
-
ABBA CORD: dCBT w/ Abatacept for aGVHD Prophylaxis
RECRUITING · Phase 2
-
Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01306019 · 40 participants · Phase 1
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- NCT01608152 · 40 participants
Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
- NCT01668082 · 40 participants · NA
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
- NCT02015013 · 40 participants · Phase 2
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia